Benefiting more patients with cardiovascular diseases: The new medicare regulations have been introduced, and aliciclizumab can be directly reimbursed

Professor Peng Daoquan prescribed alioximumab injection to patients.

Red Net Moment January 5 (reporter Liu Dan) according to the national medical insurance drug catalog to adjust the work arrangements, the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021)" has been officially launched on January 1, 2022, and the new version of the medical insurance reimbursement policy has been implemented throughout the country. On January 4, Professor Peng Daoquan of the Second Xiangya Hospital of Central South University prescribed the first prescription of the innovative lipid-lowering drug PCSK9 inhibitor Alisciumab antibody injection (Boolida) for Mr. Huang, a 58-year-old patient with coronary atherosclerotic heart disease, after entering the hospital's medical insurance, bringing a new plan for the lipid-lowering treatment of patients with atherosclerotic cardiovascular disease (ASCVD).

New lipid-lowering prescriptions allow patients to reach the target of lipids faster

Mr. Huang (pseudonym), 58, suffers from coronary atherosclerotic heart disease and has been suffering from angina for years. Because of the limited economic conditions, Mr. Huang has been using Medicare reimbursable drugs for treatment, but Mr. Huang's blood lipid control has not been ideal. On January 4, Mr. Huang came to Xiangya Second Hospital again for a follow-up examination, and Professor Peng Daoquan, who received the treatment, found that Mr. Huang's low-density lipoprotein cholesterol (LDL-C) was still at a high level.

Considering that Mr. Huang's condition is more difficult to achieve the control goals recommended by the guidelines with enhanced statin or concomitant ezezermebu, and the newly included Aliciyuzumab injection is more effective, Professor Peng Daoquan, with the consent of the patient, prescribed his first lipid-lowering prescription after the implementation of the new medical insurance regulations, using a subcutaneous injection of Aliciyumab injection (Boolida) 75 mg once every two weeks to control his blood lipids.

Subcutaneous lipid-lowering is a new attempt for Mr. Huang and many patients with atherosclerotic cardiovascular disease.

Dyslipidemia is one of the most important pathogenic risk factors for the development of atherosclerotic cardiovascular disease. Professor Peng Daoquan said that the main component of atherosclerotic plaque is "bad cholesterol - low-density lipoprotein cholesterol (LDL-C)", and the rise of "bad cholesterol" will lead to an increase in vascular garbage, blocking blood vessels, causing myocardial infarction or stroke, and even life-threatening in severe cases. Therefore, the effective control of dyslipidemia, especially the control of LDL cholesterol levels, is of great significance for the prevention and control of atherosclerotic cardiovascular disease in China.

Although statins are the basis of current lipid-lowering therapy, there are still many patients with atherosclerotic cardiovascular disease whose LDL cholesterol control is still difficult to achieve. The ODDESEY OUTCOMES study confirmed that the PCSK9 inhibitor aliccipiumab is a potent lower of LDL cholesterol levels.

New policies, new programs, lipid-lowering gospels for PATIENTS with ASCVD

Professor Peng Daoquan said that good blood lipid management can greatly reduce the risk of atherosclerotic cardiovascular disease (ASCVD), especially for those who are only high in blood lipids but have not yet had coronary heart disease, compared with the treatment after cardiovascular and cerebrovascular events, prevention is the most cost-effective treatment. Before the occurrence of cardiovascular and cerebrovascular events, lowering the blood lipid level a little lower and making the blood vessel wall cleaner can further delay the progression of atherosclerotic disease. Studies have shown that for every 1 mmol/L reduction in LDL cholesterol, the main cardiovascular event is reduced by an average of 23%.

The PCSK9 inhibitor alizeumab is able to powerfully reduce LDL cholesterol levels and reduce the risk of major adverse cardiovascular events and death. Alisciyumab is also currently the only PCSK9 inhibitor currently shown to be associated with a decrease in mortality. Many guidelines at home and abroad unanimously recommend that for people with high-risk/very high-risk atherosclerotic cardiovascular disease, intensive lipid-lowering therapy is recommended in combination with PCSK9 inhibitors.

In the past, many patients chose to use traditional treatment options because of lack of economic affordability, but blood lipid control has not been up to standard, and the disease has not been effectively controlled for a long time, which not only has an impact on the life and health of patients, but also brings a heavy burden to patients, their families and society.

With the implementation of the new medical insurance regulations, more patients in need can get more cost-effective treatment.

According to the reporter's understanding, after the new regulations of medical insurance are enabled, the innovative lipid-lowering drug PCSK9 inhibitor Aliciyuzumab injection (Bolida) will be implemented in accordance with the reimbursement policy of medical insurance Class B drugs, in Hunan Province, drugs with high clinical value and urgent needs of patients such as Alizelijumab will be implemented in accordance with the "Hunan Provincial Medical Insurance Negotiation Drug "Dual Channel" Management Measures", that is, the payment of drug costs does not set a threshold, and the segmented policy payment is not included in the hospital settlement, so as to realize the "dual channel" of insured patients' hospitalization, outpatient clinic and pharmacy. The reimbursement treatment of pharmaceutical medical insurance is unified, and the medical insurance of employees can be reimbursed by 70%, and the medical insurance of residents can be reimbursed by 60%.

The implementation of this policy can not only improve the accessibility of medication for patients with atherosclerotic cardiovascular disease, but also meet the "secondary prevention" drug demand of more patients with atherosclerotic cardiovascular disease, further reduce the economic burden of patients, and also greatly promote the development of the prevention and control of atherosclerotic cardiovascular disease in China.